Targeting the pathogenesis and boosting the therapeutic efficacy of Parkinson's disease by advanced nanoparticles DOI Creative Commons
Hanghang Liu,

Menglong Hua,

Qing Yin Zheng

и другие.

MedComm – Biomaterials and Applications, Год журнала: 2023, Номер 2(2)

Опубликована: Июнь 1, 2023

Abstract With the aging of global population, early diagnosis and treatment neurodegenerative diseases such as Parkinson's disease (PD) have attracted considerable attention. Despite great advances achieved during past decades, PD second largest is still incurable. In clinical practice, patients are mainly treated by drugs, supplemented with deep brain stimulation or nerve nucleus destruction. The existing drugs can only relieve symptoms motor disorder, cannot stop progression PD. Compared small molecular nanoparticles exhibit multiple functions in neuroprotection neurorepair due to their tunable physical chemical properties, easy modification functionalization. Herein, we first briefly review characteristics crossing blood–brain barrier, which a primary challenge for Then, summarize pathologic mechanisms comprehensively discuss novel therapy based on diverse nanoparticles, including alleviating oxidative stress, scavenging α‐synuclein aggregates, chelating metal ions, delivering neurotrophic factors genes, transplanting stem cells. This aims highlight potential advanced

Язык: Английский

Multifunctional nanoparticle-mediated combining therapy for human diseases DOI Creative Commons
Xiaotong Li,

Xiuju Peng,

Makhloufi Zoulikha

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Янв. 1, 2024

Abstract Combining existing drug therapy is essential in developing new therapeutic agents disease prevention and treatment. In preclinical investigations, combined effect of certain known drugs has been well established treating extensive human diseases. Attributed to synergistic effects by targeting various pathways advantages, such as reduced administration dose, decreased toxicity, alleviated resistance, combinatorial treatment now being pursued delivering combat major clinical illnesses, cancer, atherosclerosis, pulmonary hypertension, myocarditis, rheumatoid arthritis, inflammatory bowel disease, metabolic disorders neurodegenerative Combinatorial involves combining or co-delivering two more for a specific disease. Nanoparticle (NP)-mediated delivery systems, i.e., liposomal NPs, polymeric NPs nanocrystals, are great interest wide range due targeted delivery, extended release, higher stability avoid rapid clearance at infected areas. This review summarizes targets diseases, clinically approved combinations the development multifunctional emphasizes strategies based on severe Ultimately, we discuss challenging NP-codelivery translation provide potential approaches address limitations. offers comprehensive overview recent cutting-edge NP-mediated combination

Язык: Английский

Процитировано

112

Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential DOI Creative Commons
Martin T. Henrich, Wolfgang H. Oertel, D. James Surmeier

и другие.

Molecular Neurodegeneration, Год журнала: 2023, Номер 18(1)

Опубликована: Ноя. 11, 2023

Abstract Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD). However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs, iron chelators, have failed disease-modification clinical trials. In this review, we summarize cellular determinants impairment electron transport chain complex 1, increased oxidative stress, disturbed quality control mechanisms, bioenergetic deficiency. addition, outline pathways to neurodegeneration current context PD pathogenesis, review past treatment an attempt better understand why translational efforts thus far been unsuccessful.

Язык: Английский

Процитировано

90

A Decade of Dedication: Pioneering Perspectives on Neurological Diseases and Mental Illnesses DOI Creative Commons
Masaru Tanaka, László Vécsei

Biomedicines, Год журнала: 2024, Номер 12(5), С. 1083 - 1083

Опубликована: Май 13, 2024

Welcome to

Язык: Английский

Процитировано

17

SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close DOI Creative Commons
Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb

и другие.

Inflammopharmacology, Год журнала: 2022, Номер 31(1), С. 37 - 56

Опубликована: Дек. 29, 2022

Abstract Silent information regulator (SIRT) has distinctive enzymatic activities and physiological functions to control cell-cycle progression, gene expression, DNA stability by targeting histone non-histone proteins. SIRT1 enhances synaptic formation activity, therefore, can reduce the progression of various degenerative brain diseases including Parkinson’s disease (PD). activity is decreased aging with a subsequent increased risk for development diseases. Inhibition promotes inflammatory reactions since inhibits transcription nuclear factor kappa B (NF-κB) which also activation via microRNA miR-34a NAD synthesis. highly expressed in microglia as well neurons, antioxidant anti-inflammatory effects. Therefore, this review aimed find possible role PD neuropathology. neuroprotective effects; downregulation during p53 expression may increase vulnerability neuronal cell deaths. neuropathology linked sequence changes release pro-inflammatory cytokines due signaling pathways. In addition, oxidative stress, disorders, mitochondrial dysfunction, apoptosis contribute mutually Thus, activators play crucial mitigation through amelioration apoptosis,

Язык: Английский

Процитировано

68

Orexin pathway in Parkinson’s disease: a review DOI
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb

и другие.

Molecular Biology Reports, Год журнала: 2023, Номер 50(7), С. 6107 - 6120

Опубликована: Май 8, 2023

Язык: Английский

Процитировано

24

Sirtuin dysregulation in Parkinson's disease: Implications of acetylation and deacetylation processes DOI
Sonia Dhiman, Ashi Mannan, Ayushi Taneja

и другие.

Life Sciences, Год журнала: 2024, Номер 342, С. 122537 - 122537

Опубликована: Фев. 29, 2024

Язык: Английский

Процитировано

8

Single-nucleus multi-omics of Parkinson’s disease reveals a glutamatergic neuronal subtype susceptible to gene dysregulation via alteration of transcriptional networks DOI Creative Commons
E. Keats Shwab,

Daniel Gingerich,

Zhaohui Man

и другие.

Acta Neuropathologica Communications, Год журнала: 2024, Номер 12(1)

Опубликована: Июль 2, 2024

Abstract The genetic architecture of Parkinson’s disease (PD) is complex and multiple brain cell subtypes are involved in the neuropathological progression disease. Here we aimed to advance our understanding PD complexity at a subtype precision level. Using parallel single-nucleus (sn)RNA-seq snATAC-seq analyses simultaneously profiled transcriptomic chromatin accessibility landscapes temporal cortex tissues from 12 compared control subjects granular single resolution. An integrative bioinformatic pipeline was developed applied for these snMulti-omics datasets. results identified subpopulation cortical glutamatergic excitatory neurons with remarkably altered gene expression PD, including differentially-expressed genes within risk loci genome-wide association studies (GWAS). This only neuronal showing significant robust overexpression SNCA . Further characterization this neuronal-subpopulation showed upregulation specific pathways related axon guidance, neurite outgrowth post-synaptic structure, downregulated presynaptic organization calcium response. Additionally, characterized roles three molecular mechanisms governing PD-associated subtype-specific dysregulation expression: (1) changes cis-regulatory element transcriptional machinery; (2) abundance master regulators, YY1, SP3, KLF16; (3) candidate regulatory variants high linkage disequilibrium PD-GWAS genomic impacting transcription factor binding affinities. To knowledge, study first most comprehensive interrogation multi-omics landscape cell-subtype Our findings provide new insights into precise subtype, causal genes, non-coding underlying paving way development cell- gene-targeted therapeutics halt as well biomarkers early preclinical diagnosis.

Язык: Английский

Процитировано

8

From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders DOI Creative Commons
Elisa Duranti, Chiara Villa

Biology, Год журнала: 2024, Номер 13(9), С. 719 - 719

Опубликована: Сен. 12, 2024

Neurodegenerative diseases (NDs), like amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's (PD), primarily affect the central nervous system, leading to progressive neuronal loss motor cognitive dysfunction. However, recent studies have revealed that muscle tissue also plays a significant role in these diseases. ALS is characterized by severe wasting as result of neuron degeneration, well alterations gene expression, protein aggregation, oxidative stress. Muscle atrophy mitochondrial dysfunction are observed AD, which may exacerbate decline due systemic metabolic dysregulation. PD patients exhibit fiber atrophy, altered composition, α-synuclein aggregation within cells, contributing symptoms progression. Systemic inflammation impaired degradation pathways common among disorders, highlighting key player Understanding muscle-related changes offers potential therapeutic avenues, such targeting function, reducing inflammation, promoting regeneration with exercise pharmacological interventions. This review emphasizes importance considering an integrative approach neurodegenerative research, both peripheral pathological mechanisms, order develop more effective treatments improve patient outcomes.

Язык: Английский

Процитировано

8

NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62 DOI Creative Commons
Nikolas Furthmann, Verian Bader,

Lena Angersbach

и другие.

Nature Communications, Год журнала: 2023, Номер 14(1)

Опубликована: Дек. 19, 2023

Abstract NEMO is a ubiquitin-binding protein which regulates canonical NF-κB pathway activation in innate immune signaling, cell death regulation and host-pathogen interactions. Here we identify an NF-κB-independent function of proteostasis by promoting autophagosomal clearance aggregates. NEMO-deficient cells accumulate misfolded proteins upon proteotoxic stress are vulnerable to challenges. Moreover, patient with mutation the NEMO-encoding IKBKG gene resulting defective binding linear ubiquitin chains, developed widespread mixed brain proteinopathy, including α-synuclein, tau TDP-43 pathology. amplifies ubiquitylation at α-synuclein aggregates promotes local concentration p62 into foci. In vitro, lowers threshold concentrations required for ubiquitin-dependent phase transition p62. summary, reshapes aggregate surface efficient providing mobile interphase favoring co-condensation

Язык: Английский

Процитировано

18

The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates DOI Creative Commons
Sandesh Neupane, Elena De Cecco, Adriano Aguzzi

и другие.

Journal of Molecular Biology, Год журнала: 2022, Номер 435(12), С. 167930 - 167930

Опубликована: Дек. 22, 2022

The progressive accumulation of insoluble aggregates the presynaptic protein alpha-synuclein (α-Syn) is a hallmark neurodegenerative disorders including Parkinson's disease (PD), Multiple System Atrophy, and Dementia with Lewy Bodies, commonly referred to as synucleinopathies. Despite considerable progress on structural biology these aggregates, molecular mechanisms mediating their cell-to-cell transmission, propagation, neurotoxicity remain only partially understood. Numerous studies have highlighted stereotypical spatiotemporal spreading pathological α-Syn across different tissues anatomically connected brain regions over time. Experimental evidence from various cellular animal models indicate that transfer occurs in two defined steps: release pathogenic species infected cells, uptake via passive or active endocytic pathways. Once been internalized, little known about what drives toxicity how they interact endogenous promote its misfolding subsequent aggregation. Similarly, unknown genetic factors modulate responses aggregation species. Here we discuss current understanding phenomena associated intercellular seeds summarize supporting transmission hypothesis. Understanding involved essential develop novel targeted therapeutics against PD related

Язык: Английский

Процитировано

25